St. Cloud Surgical Center is First ASC in U.S. to Utilize Xenex Germ-Zapping Robot to Disinfect Operating Rooms & Enhance Patient Safety more

4 cheap small cap stocks I’ve got my eye for Christmas more

Southern Biologics Network Established to Create Biologics Faster and Less Expensively more

Morningside Ministries at the Manor is the First Skilled Nursing Facility in Texas to Protect Residents with Xenex Germ-Zapping Robot more

RBA to cut rates in 2015: Still want to invest in term deposits? more

Can robots help stop the Ebola outbreak? more

Robots Help Fight Ebola more

South Florida Hospital Unveils Ebola-Zapping Robot more

Sonoma Valley Hospital uses robot to kill germs more

Robots go to war against Ebola more

New iTraumaCare CEO to pursue big growth more

UAB and SRI have plans to spinoff more success more

Launch of Galderma's new acne products more

iTraumaCare’s new CEO to help company secure new funding more

U.S. Air Force Hospital Langley Adds Xenex Ebola-Zapping Robot to Inventory more

Forthcoming Acne Treatment Made With Exclusive (And Sustainable) East Indian Sandalwood Oil more

Sonoma Valley Hospital Acquires Xenex Germ-Killing Robot to Enhance Patient Safety more

Robot fights germs at Sharp Chula Vista Medical Center more

Xenex updates protocols for germ-zapping robots in response to Ebola threat more

How do we get rid of the endotoxins? Birmingham's  has the solution more

Medical Device ® Positions New Leader for Next-Level Growth more

The Xenex robot at South Shore Hospital featured on an Xploration Earth more

Germ-zapping robot Gigi sets its sights on Ebola more

Morningside Ventures leads a Series B round for DNAtrix more

StemBioSys secures new research space at BioBridge Global more

Birmingham's Soluble Therapeutics acquires Seattle company Dilyx Biotechnology more

Company invents germ-zapping robot more

Xenex Congratulates Houston Cancer Hospital more

Australian grown Indian Sandalwood timber attracts lucrative Asian markets more

DNATRIX ANNOUNCES TREATMENT OF FIRST PATIENT WITH DNX-2401 more

Targeted Technology raises more than $40 million more

Reducing Healthcare Associated Infections (HAIs): Not All UV Light is the Same more

Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO more

Three Birmingham companies recognized in PwC report more

Former Kinetic Concepts Inc. CEO to lead StemBioSys

San Antonio-based biomedical company StemBioSys Inc. has tapped Catherine Burzik to serve as chairman of the company’s board of directors.

Burzik previously served as president, CEO and director Kinetic Concepts Inc., a medical device and regenerative medicine company that is also based in San Antonio. She has been an advisor to StemBioSys since early 2012 and is currently a general partner in Targeted Technology, an early stage venture capital firm concentrating on medical device, life sciences and biotech investments. Burzik succeeds StemBioSys founder Dr. Steven A. Davis.

In a separate move, StemBioSys has named Robert Hutchens as its new CEO. He is replacing Peter Savas as CEO, who left the company earlier this year to return to Boston. John W. Feik had served as interim CEO since May.

Hutchens comes to StemBioSys from New York, where he spent the last 11 years as a partner with international consulting firm Booz & Company. Hutchens played a key role with the firm’s health care practice, both in the U.S. and Europe, working with pharmaceutical and medical device manufacturers. He was also engaged in projects with the Centers for Disease Control and with a number of bio-terrorism defense efforts.

Davis and Feik will both remain with StemBioSys in director roles.

“It is a real coup for us, as a young company, to be able to secure Cathy Burzik and Bob Hutchens for these two key positions,” Davis explains. “They bring extraordinary leadership and industry experience to StemBioSys at this critical stage of our development. Their involvement speaks volumes about the confidence they have in the potential of the company’s patented and proprietary stem cell technology platforms.”

Says Burzik, “StemBioSys has very promising proprietary life science products which will accelerate research and therapy development in the rapidly growing field of stem cell-based regenerative medicine. Dr. Davis saw that potential early-on and built the company around that science and technology.”

San Antonio-based Targeted Technologies was the lead investor in StemBioSys’ recent Series A funding round.

“Our early-stage venture fund, Targeted Technologies, is highly encouraged with the progress that StemBioSys is making in both research and product development,” Burzik adds. “We look forward to product commercialization within the next year.”

Hutchens says there is “no question that StemBioSys can achieve a leadership role” in the stem cell research and regenerative medicine arenas.

Source: http://www.bizjournals.com/sanantonio/blog/2014/08/former-kinetic-concepts-inc-ceo-to-lead-stembiosys.html?page=all  back

International dermatology company Galderma confirmed more

AUSTRALIAN Sandalwood producer TFS Corporation will supply oil more

San Antonio luring biotech firms with venture capital more

Biotech firm secures nearly $5 million in funding, is relocating to San Antonio more

Birmingham is on the front lines of medical research: take a look at this incredible biotech startup more

Germ-Zapping Robots Fight C. diff and MRSA at Mercy Health Saint Mary's more

Milford hospital enlists robots in war against infections more

Xenex Testifies About UV Room Disinfection Technology Effectiveness to U.S. House of Representatives more

Western Pa. hospitals test robot using ultraviolet rays to kill bacteria more

Xenex Demonstrates UV Room Cleaning System’s Effectiveness in Reducing Hospital Acquired Infections more

TFS flags record full-year profit more

Sweet scented sandalwood flavour of month more

House committee looks for new technology in Veterans Affairs hospitals more

FDA grants fast track status to drug DNX-2401 for recurrent Glioblastoma more

CEO shakeup at San Antonio biotech company StemBioSys more

First harvest to be completed in June more

BiO2 Medical Enrolls Subjects in the New U.S. FDA Early Feasibility Pilot Study for the Angel® Catheter more

San Antonio biotech firm readies skin treatment for distribution more

ViroXis Gets Approval To Initiate FDA Phase 2 Study For Molluscum Contagiosum more

Medical technologies conference announces speaker lineup more

Australian sandalwood sells for millions more

Sandalwood exports as good as gold more

Santalis Pharmaceuticals Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize OTC Dermatology Products more

ViroXis Corporation Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize an OTC Dermatology Product more

DNAtrix Awarded $10.8 Million Grant by the Cancer Prevention and Research Institute of Texas more

ViroXis Corporation Achieves Key Clinical Milestones more

There are growing concerns about the threat of an antibiotic crisis caused by the spread of drug-resistant superbugs. Those concerns could result in more